Ambulero
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. They develop innovative treatments using stromal cells engineered to express E-selectin and gene therapy vectors to promote tissue repair and regeneration, aiming to treat vascular diseases and non-healing wounds.
Industries
Nr. of Employees
small (1-50)
Products
AAV gene therapy candidate for rare vascular disease (E-selectin delivery)
A first-in-class adeno-associated virus (AAV) gene therapy approach designed to deliver and overexpress a cell adhesion molecule in diseased vascular tissues to promote regeneration and prevent limb/tissue loss.
AAV gene therapy candidate for critical limb ischemia (E-selectin delivery)
AAV-based gene therapy intended to overexpress a therapeutic adhesion molecule in ischemic tissues as a nonsurgical adjunct to improve perfusion and reduce amputation risk in critical limb ischemia.
Allogeneic MSC-based cell therapy engineered to express therapeutic transgene
An allogeneic mesenchymal stromal cell product transduced ex vivo to express a therapeutic adhesion molecule, developed to accelerate wound healing and tissue repair in ischemic and non-healing wounds.
AAV gene therapy candidate for rare vascular disease (E-selectin delivery)
A first-in-class adeno-associated virus (AAV) gene therapy approach designed to deliver and overexpress a cell adhesion molecule in diseased vascular tissues to promote regeneration and prevent limb/tissue loss.
AAV gene therapy candidate for critical limb ischemia (E-selectin delivery)
AAV-based gene therapy intended to overexpress a therapeutic adhesion molecule in ischemic tissues as a nonsurgical adjunct to improve perfusion and reduce amputation risk in critical limb ischemia.
Allogeneic MSC-based cell therapy engineered to express therapeutic transgene
An allogeneic mesenchymal stromal cell product transduced ex vivo to express a therapeutic adhesion molecule, developed to accelerate wound healing and tissue repair in ischemic and non-healing wounds.
Services
Research collaborations and partnerships
Engagement with academic and industry partners to co-develop gene and cell therapy programs and to support translational research.
Research collaborations and partnerships
Engagement with academic and industry partners to co-develop gene and cell therapy programs and to support translational research.
Expertise Areas
- AAV gene therapy development
- Mesenchymal stromal cell (MSC) engineering
- Preclinical vascular regeneration and wound-healing models
- IND preparation and regulatory strategy for rare diseases
Key Technologies
- AAV gene delivery
- Codon optimization and de novo vector synthesis
- Ex vivo viral transduction of MSCs
- Allogeneic mesenchymal stromal cell therapy